Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Fasching

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Thrombosis and Haemostasis|September 1, 1996
Elevated circulating P-selectin in insulin dependent diabetes mellitusB Jilma, P Fasching, C Ruthner, et al.
Diabetes|April 1, 1997
Nitric oxide and ocular blood flow in patients with IDDML Schmetterer, O Findl, P Fasching, et al.
Amino Acids|November 7, 2013
Influence ofL-arginine on glucose mediated collagen cross link precursors in patients with diabetes mellitusG Lubec, H Vierhapper, A J Bailey, et al.
Ultraschall in Der Medizin (Stuttgart, Germany : 1980)|December 18, 2010
New diagnostic criteria in real-time elastography for the assessment of breast lesionsB R Adamietz, M Meier-Meitinger, P Fasching, et al.
Diabetes|September 2, 2000
Endothelin 1 transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cellsP Quehenberger, A Bierhaus, P Fasching, et al.
Diabetes|November 14, 1997
Renal and ocular hemodynamic effects of insulinL Schmetterer, M Müller, P Fasching, et al.
Geburtshilfe Und Frauenheilkunde|May 31, 2016
Willingness of Patients with Breast Cancer in the Adjuvant and Metastatic Setting to Use Electronic Surveys (ePRO) Depends on Sociodemographic Factors, Health-related Quality of Life, Disease Status and Computer SkillsJ Graf, E Simoes, K Wißlicen, et al.
Breast (Edinburgh, Scotland)|March 2, 2019
Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA studyA Mavratzas, S Baek, B Gerber, et al.
Plos One|June 7, 2017
The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trialB A S Jaeger, J Neugebauer, U Andergassen, et al.
ESMO Open|April 25, 2024
Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)P Meyer-Wilmes, J Huober, M Untch, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Thrombosis and Haemostasis|September 1, 1996
Elevated circulating P-selectin in insulin dependent diabetes mellitusB Jilma, P Fasching, C Ruthner, et al.
Diabetes|April 1, 1997
Nitric oxide and ocular blood flow in patients with IDDML Schmetterer, O Findl, P Fasching, et al.
Amino Acids|November 7, 2013
Influence ofL-arginine on glucose mediated collagen cross link precursors in patients with diabetes mellitusG Lubec, H Vierhapper, A J Bailey, et al.
Ultraschall in Der Medizin (Stuttgart, Germany : 1980)|December 18, 2010
New diagnostic criteria in real-time elastography for the assessment of breast lesionsB R Adamietz, M Meier-Meitinger, P Fasching, et al.
Diabetes|September 2, 2000
Endothelin 1 transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cellsP Quehenberger, A Bierhaus, P Fasching, et al.
Diabetes|November 14, 1997
Renal and ocular hemodynamic effects of insulinL Schmetterer, M Müller, P Fasching, et al.
Geburtshilfe Und Frauenheilkunde|May 31, 2016
Willingness of Patients with Breast Cancer in the Adjuvant and Metastatic Setting to Use Electronic Surveys (ePRO) Depends on Sociodemographic Factors, Health-related Quality of Life, Disease Status and Computer SkillsJ Graf, E Simoes, K Wißlicen, et al.
Breast (Edinburgh, Scotland)|March 2, 2019
Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA studyA Mavratzas, S Baek, B Gerber, et al.
Plos One|June 7, 2017
The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trialB A S Jaeger, J Neugebauer, U Andergassen, et al.
ESMO Open|April 25, 2024
Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)P Meyer-Wilmes, J Huober, M Untch, et al.
Pageof 5